Ohashi Akihiro

Affiliation and department：
Job title： Division Head
Homepage URL (1)： https://www.ncc.go.jp/jp/epoc/division/translational_genomics/kashiwa/members/20180914101020.html

Research field (1)： Tumor biology

Research theme for competitive and other funds (5)：

2024 - 2028 Development of preventive and therapeutic strategies for age-related chronic inflammation by targeting senescence-associated T cells
2022 - 2025 癌細胞における染色体不安定性が引き起こす細胞内ストレス反応
2020 - 2024 A novel germline mutation in the non-coding region of BRCA2 is associated with hereditary breast cancer
2020 - 2023 新規CDC7キナーゼ阻害剤TAK-931の併用療法開発に向けた橋渡し研究
2019 - 2021 癌細胞における染色体不安定性が引き起こす細胞内ストレス反応

Papers (57)：

Kosuke Tanaka, Yasuki Adachi, Miyuki Yoshiya, Takuya Owari, Tomoko Yamamori-Morita, Akihiro Ohashi, Susumu Kobayashi, Shohei Koyama, Hiroyoshi Nishikawa. Abstract 5265: Targeting mtDNA dynamics enhances immunogenicity and sensitizes KRAS mutant cancers to PD-1 blockade. Cancer Research. 2024. 84. 6_Supplement. 5265-5265
Pinyi Lu, Ryo Kamata, Michael R. Weil, Naomi Ohashi, Akihiro Ohashi, Eric A. Stahlberg. Abstract 4945: Computational modeling-based discovery of novel anticancer drug candidates targeting centromere-associated protein E. Cancer Research. 2024. 84. 6_Supplement. 4945-4945
Ryo Kamata, Hitoshi Saito, Yumi Hakozaki, Yukie Kashima, Gaku Yamamoto, Tomoko Yamamori Morita, Pinyi Lu, Akihiro Ohashi. Abstract 411: PI3K-AKT-mTOR signaling pathways play important roles in chromosomal instability-induced innate immune response in cancer cells. Cancer Research. 2024. 84. 6_Supplement. 411-411
Gaku Yamamoto, Kosuke Tanaka, Ryo Kamata, Takehiro Nakao, Shunta Mori, Jie Liu, Susumu S. Kobayashi, Akihiro Ohashi. Abstract 1938: WEE1 inhibition prevents and overcomes resistance to KRAS inhibitors in lung cancer by enhancing MCL1-mediated apoptosis. Cancer Research. 2024. 84. 6_Supplement. 1938-1938
Tetsumori Yamashima, Daria Mochly-Rosen, Soichi Wakatsuki, Eishiro Mizukoshi, Takuya Seike, Isabel Maria Larus, Che-Hong Chen, Miho Takemura, Hisashi Saito, Akihiro Ohashi. Cleavage of Hsp70.1 causes lysosomal cell death under stress conditions. Frontiers in molecular biosciences. 2024. 11. 1378656-1378656

ｍore...

MISC (27)：

Hiroki Yamashita, Jason Guoqiang Zhang, Chiaki Mashima, Ryo Kamata, Tomoko Yamamori, Izuma Nakayama, Akihito Kawazoe, Kohei Shitara, Tomonori Yano, Qunli Xu, et al. Abstract 5075: Transcriptomic landscape of tumor microenvironment in gastric cancer in treatment with different types of cancer drugs. Cancer Research. 2024. 84. 6_Supplement. 5075-5075
Gaku Yamamoto, Kosuke Tanaka, Ryo Kamata, Shunta Mori, Jie Liu, Toyohiro Yamauchi, Yuta Sakae, Akihiro Ohashi, Susumu S. Kobayashi. Abstract 5739: Targeting WEE1 to improve the therapy of KRAS G12C mutant non-small cell lung cancer. Cancer Research. 2023. 83. 7_Supplement. 5739-5739
大橋紹宏. ROSをターゲットとしたAg5の細胞死メカニズム. がんと代謝研究会プログラム&抄録集. 2023. 9th
鎌田諒, 大橋紹宏. CENP-E inhibitors induce chromosome misalignment, micronucleus formation and immune response. 日本がん分子標的治療学会学術集会プログラム・抄録集. 2023. 27th
大橋紹宏, 鎌田諒. Elucidation of the mechanism of cell death induction by Ag5, a novel low-atomic cluster targeting the antioxidant system. 日本がん分子標的治療学会学術集会プログラム・抄録集. 2023. 27th

ｍore...

Patents (5)：

Combination therapy for cancer treatment
Combination therapy for cancer treatment
Cancer treatment methods based on tp53 mutation status and hypermutation status
Method of predicting effects of cdc7 inhibitor
Therapeutic agent for cancer

Education (2)：

1997 - 2002 Kyoto University Gradulate School of Agriculture Applied Bioscience
1993 - 1997 Kyoto University Department of Agriculture

Work history (11)：

2023/02 - 現在アステラス製薬株式会社(クロスアポイントメント) イムノオンコロジー Principal Investigator
2022/04 - 現在 The University of Tokyo Graduate School of Frontier Sciences
2020/04 - 現在 Tokyo University of Science
2018/09 - 現在 National Cancer Center Exploratory Oncology Research & Clinical Trial Center Division Head
2017/05 - 2018/08 Takeda Pharmaceuticals Internationals Inc. Oncology Drug Disovery Unit Senior Scientist

Show all

Association Membership(s) (3)：

日本分子生物学会 , THE JAPANESE ASSOCIATION FOR MOLECULAR TARGET THERAPY OF CANCER , THE JAPANESE CANCER ASSOCIATION

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page